ClinicalTrials.gg
CompletedNCT01885078RA-BEYONDUpdated Apr 25, 2022Results posted

An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

A Phase 3 interventional study of Baricitinib and Placebo in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 409 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,877
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Enrollment
Largest of 23
2,877 · median 290
Started
2013
with 1 other
Phase 3
8 of 23
1 open now
Registered
9th of 23
by date
Lead sponsor
11 of 23
Eli Lilly and Company

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one has the largest enrollment, is one of 2 that started in 2013, is one of 8 in phase 3, and was the 9th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study.

The study provides 7 years of additional treatment with baricitinib.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have completed the final active treatment in study JADV (NCT01710358), JADZ (NCT01711359), JADX (NCT01721057), JADW (NCT01721044), JADA (NCT01185353) or JAGS (NCT02265705)

Exclusion criteria

Exclusion Criteria:

  • Have significant uncontrolled cerebro-cardiovascular (eg, myocardial infarction [MI], unstable angina, unstable arterial hypertension, severe heart failure, or cerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neuropsychiatric disorders, or abnormal laboratory values that developed during a previous baricitinib study that, in the opinion of the investigator, pose an unacceptable risk to the participant if product continues to be administered
  • Have a known to baricitinib or any component of this investigational product
  • Had investigational product permanently discontinued at any time during a previous baricitinib study
  • Had temporary investigational product interruption at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for participation in the study
  • Have any other condition that, in the opinion of the investigator, renders the participant unable to understand the nature, scope, and possible consequences of the study or precludes the participant from following and completing the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,877 participants (actual)

Study arms

  • Experimental
    4 milligram (mg) Baricitinib

    4 mg Baricitinib administered orally once daily. Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    2 mg Baricitinib

    2 mg Baricitinib administered orally once daily. Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    2 mg Baricitinib Step-down

    2 mg Baricitinib administered orally once daily in the 96-week Step-down period. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.

    Drug: Baricitinib

  • Experimental
    4 mg Baricitinib Step-down

    4 mg Baricitinib administered orally once daily in the 96-week Step-down period. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.

    Drug: Baricitinib

Interventions

  • Administered orally

    Also known as: LY 3009104, INCB 028050

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Adverse Events (AEs) or Serious AE

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (i.e., abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Non-serious AEs are reported at a threshold of 5%. An SAE is an AE from this study that results in any of the following: death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, considered significant by the investigator for any other reason A summary of serious adverse events (SAEs) and other non-serious adverse events (AEs), regardless of causality, were reported in the Reported Adverse Events module.

    Time frame: Baseline through 84 Months

Secondary outcomes

  1. Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100

    Time frame: Year 1 after entry into JADY

  2. Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100

    Time frame: Year 3 after entry into JADY

  3. Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100

    Time frame: Year 5 after entry into JADY

  4. Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50

    ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100

    Time frame: Year 1 after entry into JADY

  5. Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50

    ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100

    Time frame: Year 3 after entry into JADY

  6. Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50

    ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100

    Time frame: Year 5 after entry into JADY

  7. Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70

    ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100

    Time frame: Year 1 after entry into JADY

  8. Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70

    ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100

    Time frame: Year 3 after entry into JADY

  9. Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70

    ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100

    Time frame: Year 5 after entry into JADY

  10. Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Year 1 after entry into JADY

  11. Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Year 3 after entry into JADY

  12. Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Year 5 after entry into JADY

  13. Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Year 1 after entry into JADY

  14. Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Year 3 after entry into JADY

  15. Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Year 5 after entry into JADY

  16. Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2

    DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Year 1 after entry into JADY

  17. Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2

    DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Year 3 after entry into JADY

  18. Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2

    DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Year 5 after entry into JADY

  19. Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6

    DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Year 1 after entry into JADY

  20. Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6

    DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Year 3 after entry into JADY

  21. Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6

    DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Year 5 after entry into JADY

  22. Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response

    Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.

    Time frame: Year 1 after entry into JADY

  23. Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response

    Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.

    Time frame: Year 3 after entry into JADY

  24. Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response

    Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.

    Time frame: Year 5 after entry into JADY

  25. Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)

    X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

    Time frame: Baseline, Year 1

  26. Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)

    X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

    Time frame: Baseline, Year 3

  27. Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)

    X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

    Time frame: Baseline, Year 5

  28. Percentage of Participants With mTSS Change ≤0

    X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.

    Time frame: Year 1 after entry into JADY

  29. Percentage of Participants With mTSS Change ≤0

    X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.

    Time frame: Year 3 after entry into JADY

  30. Percentage of Participants With mTSS Change ≤0

    X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.

    Time frame: Year 5 after entry into JADY

  31. Change From Baseline of Originating Study in Joint Space Narrowing at Year 1

    X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.

    Time frame: Baseline, Year 1

  32. Change From Baseline of Originating Study in Joint Space Narrowing at Year 3

    X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.

    Time frame: Baseline, Year 3

  33. Change From Baseline of Originating Study in Joint Space Narrowing at Year 5

    X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing

    Time frame: Baseline, Year 5

  34. Change From Baseline of Originating Study in Duration of Morning Stiffness

    Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

    Time frame: Baseline, Year 1

  35. Change From Baseline of Originating Study in Duration of Morning Stiffness

    Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

    Time frame: Baseline, Year 3

  36. Change From Baseline of Originating Study in Duration of Morning Stiffness

    Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

    Time frame: Baseline, Year 5

  37. Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores

    The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.

    Time frame: Baseline, Year 1

  38. Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores

    The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.

    Time frame: Baseline, Year 3

  39. Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores

    The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.

    Time frame: Baseline, Year 5

  40. Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)

    The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.

    Time frame: Baseline, Year 1

  41. Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)

    The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.

    Time frame: Baseline, Year 3

  42. Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)

    The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.

    Time frame: Baseline, Year 5

  43. Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10

    The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

    Time frame: Year 1 after entry into JADY

  44. Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10

    The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

    Time frame: Year 3 after entry into JADY

  45. Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10

    The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

    Time frame: Years 5 after entry into JADY

  46. Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤ 2.8

    The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

    Time frame: Year 1 after entry into JADY

  47. Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8

    The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

    Time frame: Year 3 after entry into JADY

  48. Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8

    The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

    Time frame: Year 5 after entry into JADY

  49. Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

    Time frame: Year 1 after entry into JADY

  50. Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

    Time frame: Year 3 after entry into JADY

  51. Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

    Time frame: Year 5 after entry into JADY

  52. Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

    Time frame: Year 1 after entry into JADY

  53. Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

    Time frame: Year 3 after entry into JADY

  54. Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

    Time frame: Year 5 after entry into JADY

  55. Change From Baseline of Originating Study in Bone Erosion Score

    The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.

    Time frame: Baseline, Year 1

  56. Change From Baseline of Originating Study in Bone Erosion Score

    The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.

    Time frame: Baseline, Year 3

  57. Change From Baseline of Originating Study in Bone Erosion Score

    The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.

    Time frame: Baseline, Year 5

  58. Healthcare Resource Utilization

    Number of visits to medical care providers related to treatment of Rheumatoid Arthritis (RA) outside of the clinical study. Reported here are healthcare consultations and emergency room consultations from end of originating study to end of participation in study JADY.

    Time frame: Baseline up to 84 Months

  59. Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11

    SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.

    Time frame: Year 1 after entry into JADY

  60. Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11

    SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.

    Time frame: Year 3 after entry into JADY

  61. Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11

    SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.

    Time frame: Year 5 after entry into JADY

  62. Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3

    SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.

    Time frame: Year 1 after entry into JADY

  63. Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3

    SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.

    Time frame: Year 3 after entry into JADY

  64. Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3

    SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.

    Time frame: Year 5 after entry into JADY

  65. Percentage of Participants With Relapse Event During the 96-Week Step-Down Period

    Relapse is defined as a Clinical Disease Activity Index score \> 10. The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. Total number of participants at risk multiplied by estimate of cumulative event probability would need to be rounded up or down to get a whole number.

    Time frame: Week 0 through Week 96 of Step-down

07

Results

Posted Feb 1, 2022

Participant flow

Participants were eligible to participate in the Step-down period if they achieved a sustained (at least 3 months in JADY) low disease activity (CDAI score ≤10; for participants originating in Studies JADV, JADX, JADW, and JAGS) or sustained remission (CDAI score ≤2.8; for participants originating in Study JADZ). Eligible participants were randomized to 4 mg or 2 mg baricitinib once daily to evaluate if treatment with 2 mg maintains the low disease activity achieved with 4 mg baricitinib.

Treatment Period
Participant flow — Treatment Period
MilestoneJADZ 4 Milligram (mg) BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib2 mg Baricitinib Step-down4 mg Baricitinib Step-down
Started45110911804031173312218300
Received at least once dose of study drug45110901804031173312218300
Completed196449120278105500
Not completed4321027131283902502212800
Withdrew: Adverse event521363073177224500
Withdrew: Death1333592103200
Withdrew: Lack of efficacy1233102324589500
Withdrew: Lost to follow-up161979282000
Withdrew: Physician decision19215129244300
Withdrew: Protocol violation3503160000
Withdrew: Sponsor decision24564849902038162300
Withdrew: Withdrawal by subject7213225631534171000
Withdrew: Other0001000000
Step-down Period
Participant flow — Step-down Period
MilestoneJADZ 4 Milligram (mg) BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib2 mg Baricitinib Step-down4 mg Baricitinib Step-down
Started00000000592594
Complete through week 9600000000407455
Completed00000000523533
Not completed000000006961
Withdrew: Sponsor decision0000000011
Withdrew: Adverse event000000002938
Withdrew: Withdrawal by subject000000002515
Withdrew: Physician decision0000000072
Withdrew: Death0000000043
Withdrew: Lost to follow-up0000000011
Withdrew: Lack of efficacy0000000010
Withdrew: Protocol violation0000000011

Outcome measures

PrimaryNumber of Participants Who Experienced Adverse Events (AEs) or Serious AE

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (i.e., abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Non-serious AEs are reported at a threshold of 5%. An SAE is an AE from this study that results in any of the following: death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, considered significant by the investigator for any other reason A summary of serious adverse events (SAEs) and other non-serious adverse events (AEs), regardless of causality, were reported in the Reported Adverse Events module.

Time frame:
Baseline through 84 Months
Reported as:
Number · participants
Number of Participants Who Experienced Adverse Events (AEs) or Serious AE
participants2 mg Baricitinib4 mg Baricitinib2 mg Baricitinib Step-down4 mg Baricitinib Step-down
Adverse Events2341532270315
Serious Adverse Events112517164178
SecondaryPercentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100

Time frame:
Year 1 after entry into JADY
Reported as:
Number · Percentage of Participants
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20
Percentage of ParticipantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR2092.6 (89.7 to 94.7)88.4 (86.3 to 90.2)79.3 (72.6 to 84.7)79.5 (75.1 to 83.3)72.3 (62.9 to 80.1)70.8 (65.2 to 75.9)86.7 (81.4 to 90.6)75.6 (65.1 to 83.8)
SecondaryPercentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR2078.3 (74.1 to 82.0)76.6 (73.9 to 79.1)71.6 (64.4 to 77.9)70.5 (65.6 to 74.9)57.4 (47.7 to 66.6)55.8 (49.9 to 61.6)73.8 (67.5 to 79.3)71.8 (61.0 to 80.6)
SecondaryPercentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR2067.3 (62.7 to 71.6)65.6 (62.6 to 68.4)60.4 (52.8 to 67.4)56.0 (50.9 to 61.0)50.5 (40.9 to 60.0)43.1 (37.3 to 49.0)24.8 (19.4 to 31.0)60.3 (49.2 to 70.4)
SecondaryPercentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50

ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR5080.0 (75.9 to 83.5)67.7 (64.8 to 70.5)58.0 (50.5 to 65.2)58.2 (53.1 to 63.1)45.5 (36.2 to 55.2)43.8 (38.0 to 49.7)69.0 (62.5 to 74.9)43.6 (33.1 to 54.6)
SecondaryPercentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50

ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR5067.8 (63.2 to 72.1)61.6 (58.6 to 64.5)49.7 (42.3 to 57.2)53.3 (48.2 to 58.3)43.6 (34.3 to 53.3)36.5 (31.0 to 42.3)59.0 (52.3 to 65.5)43.6 (33.1 to 54.6)
SecondaryPercentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50

ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR5059.9 (55.1 to 64.5)52.7 (49.7 to 55.7)44.4 (37.1 to 51.9)43.2 (38.2 to 48.3)37.6 (28.8 to 47.4)32.1 (26.9 to 37.9)18.6 (13.9 to 24.4)37.2 (27.3 to 48.3)
SecondaryPercentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70

ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR7061.3 (56.6 to 65.9)45.7 (42.7 to 48.8)34.9 (28.1 to 42.4)35.8 (31.1 to 40.8)28.7 (20.8 to 38.2)25.9 (21.1 to 31.4)42.9 (36.4 to 49.6)26.9 (18.3 to 37.7)
SecondaryPercentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70

ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR7054.4 (49.6 to 59.1)44.1 (41.1 to 47.1)35.5 (28.7 to 43.0)32.5 (27.9 to 37.5)24.8 (17.4 to 34.0)21.5 (17.1 to 26.8)35.2 (29.1 to 41.9)21.8 (14.1 to 32.2)
SecondaryPercentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70

ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70
percentage of participantsJADZ 4 Milligram (mg) BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR7048.2 (43.5 to 53.0)39.1 (36.1 to 42.1)28.4 (22.1 to 35.6)28.4 (24.0 to 33.2)23.8 (16.5 to 32.9)18.2 (14.1 to 23.2)12.9 (9.0 to 18.1)19.2 (12.0 to 29.3)
SecondaryPercentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.281.9 (77.9 to 85.3)71.9 (69.0 to 74.5)66.3 (58.9 to 73.0)68.6 (63.7 to 73.1)50.5 (40.9 to 60.0)51.1 (45.2 to 57.0)72.4 (66.0 to 78.0)59.0 (47.9 to 69.2)
SecondaryPercentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.271.8 (67.3 to 75.9)65.5 (62.5 to 68.3)59.2 (51.6 to 66.3)59.3 (54.2 to 64.2)47.5 (38.1 to 57.2)41.6 (35.9 to 47.5)61.0 (54.2 to 67.3)60.3 (49.2 to 70.4)
SecondaryPercentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.261.1 (56.3 to 65.6)58.9 (55.9 to 61.9)46.7 (39.4 to 54.3)50.0 (44.9 to 55.1)44.6 (35.2 to 54.3)34.3 (28.9 to 40.1)21.0 (16.0 to 27.0)53.8 (42.9 to 64.5)
SecondaryPercentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6
percentage of participantsJADZ 4 Milligram (mg) BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.665.6 (61.0 to 70.0)52.3 (49.3 to 55.4)50.9 (43.4 to 58.3)46.2 (41.1 to 51.3)34.7 (26.1 to 44.3)32.8 (27.6 to 38.6)52.4 (45.6 to 59.0)44.9 (34.3 to 55.9)
SecondaryPercentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.659.9 (55.1 to 64.5)51.0 (47.9 to 54.0)43.8 (36.5 to 51.3)43.2 (38.2 to 48.3)31.7 (23.4 to 41.3)26.3 (21.4 to 31.8)38.6 (32.2 to 45.3)35.9 (26.1 to 47.0)
SecondaryPercentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.651.1 (46.3 to 55.8)44.0 (41.0 to 47.0)36.1 (29.2 to 43.6)37.7 (32.9 to 42.8)29.7 (21.7 to 39.2)26.6 (21.8 to 32.2)13.3 (9.4 to 18.6)43.6 (33.1 to 54.6)
SecondaryPercentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2

DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.261.8 (57.1 to 66.3)48.4 (45.3 to 51.4)46.2 (38.8 to 53.7)48.4 (43.3 to 53.5)31.7 (23.4 to 41.3)31.8 (26.5 to 37.5)41.0 (34.5 to 47.7)35.9 (26.1 to 47.0)
SecondaryPercentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2

DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.254.4 (49.6 to 59.1)46.1 (43.1 to 49.2)40.2 (33.1 to 47.8)41.0 (36.1 to 46.1)22.8 (15.7 to 31.9)23.7 (19.1 to 29.1)33.8 (27.8 to 40.4)37.2 (27.3 to 48.3)
SecondaryPercentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2

DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.248.7 (43.9 to 53.5)41.3 (38.3 to 44.3)36.1 (29.2 to 43.6)32.5 (27.9 to 37.5)23.8 (16.5 to 32.9)21.9 (17.4 to 27.2)11.4 (7.8 to 16.4)37.2 (27.3 to 48.3)
SecondaryPercentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6

DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.636.8 (32.3 to 41.5)29.3 (26.6 to 32.2)24.3 (18.4 to 31.2)26.8 (22.5 to 31.5)20.8 (14.0 to 29.7)13.1 (9.6 to 17.7)25.2 (19.8 to 31.5)15.4 (9.0 to 25.0)
SecondaryPercentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6

DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.638.9 (34.4 to 43.7)24.7 (22.1 to 27.4)24.3 (18.4 to 31.2)23.2 (19.2 to 27.8)15.8 (10.0 to 24.2)10.2 (7.2 to 14.4)19.5 (14.7 to 25.4)23.1 (15.1 to 33.6)
SecondaryPercentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6

DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.631.3 (27.0 to 35.9)23.9 (21.4 to 26.6)22.5 (16.8 to 29.4)19.4 (15.7 to 23.8)11.9 (6.9 to 19.6)8.8 (6.0 to 12.7)7.1 (4.4 to 11.4)19.2 (12.0 to 29.3)
SecondaryPercentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response

Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response30.5 (26.3 to 35.1)20.8 (18.4 to 23.4)17.8 (12.7 to 24.2)17.8 (14.2 to 22.0)8.9 (4.8 to 16.1)9.5 (6.6 to 13.5)17.1 (12.6 to 22.8)12.8 (7.1 to 22.0)
SecondaryPercentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response

Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response30.8 (26.6 to 35.4)20.3 (18.0 to 22.9)16.6 (11.7 to 22.9)15.0 (11.7 to 19.1)9.9 (5.5 to 17.3)8.0 (5.4 to 11.9)11.9 (8.2 to 17.0)15.4 (9.0 to 25.0)
SecondaryPercentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response

Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response26.5 (22.5 to 30.9)17.7 (15.5 to 20.1)13.6 (9.2 to 19.6)14.2 (11.0 to 18.2)6.9 (3.4 to 13.6)7.3 (4.8 to 11.0)5.2 (2.9 to 9.1)15.4 (9.0 to 25.0)
SecondaryChange From Baseline of Originating Study in Modified Total Sharp Score (mTSS)

X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

Time frame:
Baseline, Year 1

No measurements were reported for this outcome.

SecondaryChange From Baseline of Originating Study in Modified Total Sharp Score (mTSS)

X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

Time frame:
Baseline, Year 3
Reported as:
Least squares mean · score on a scale
Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)
score on a scaleJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)1.30 (0.94 to 1.67)1.64 (1.38 to 1.90)1.13 (0.61 to 1.66)1.13 (0.78 to 1.48)——1.20 (0.61 to 1.80)—
SecondaryChange From Baseline of Originating Study in Modified Total Sharp Score (mTSS)

X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

Time frame:
Baseline, Year 5
Reported as:
Least squares mean · score on a scale
Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)
score on a scaleJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)1.64 (1.18 to 2.09)2.18 (1.85 to 2.51)1.32 (0.69 to 1.96)1.58 (1.15 to 2.02)————
SecondaryPercentage of Participants With mTSS Change ≤0

X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.

Time frame:
Year 1 after entry into JADY

No measurements were reported for this outcome.

SecondaryPercentage of Participants With mTSS Change ≤0

X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants With mTSS Change ≤0
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants With mTSS Change ≤053.5 (48.7 to 58.2)53.0 (50.0 to 56.0)0.6 (0.1 to 3.3)0.8 (0.3 to 2.4)——0 (0.0 to 1.8)—
SecondaryPercentage of Participants With mTSS Change ≤0

X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants With mTSS Change ≤0
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants With mTSS Change ≤01.7 (0.8 to 3.4)0.6 (0.3 to 1.3)0 (0.0 to 2.2)0.5 (0.1 to 2.0)——0 (0.0 to 1.8)—
SecondaryChange From Baseline of Originating Study in Joint Space Narrowing at Year 1

X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.

Time frame:
Baseline, Year 1

No measurements were reported for this outcome.

SecondaryChange From Baseline of Originating Study in Joint Space Narrowing at Year 3

X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.

Time frame:
Baseline, Year 3
Reported as:
Least squares mean · score on a scale
Change From Baseline of Originating Study in Joint Space Narrowing at Year 3
score on a scaleJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in Joint Space Narrowing at Year 30.45 (0.26 to 0.63)0.72 (0.59 to 0.86)0.54 (0.25 to 0.83)0.44 (0.24 to 0.63)——0.52 (0.23 to 0.82)—
SecondaryChange From Baseline of Originating Study in Joint Space Narrowing at Year 5

X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing

Time frame:
Baseline, Year 5
Reported as:
Least squares mean · score on a scale
Change From Baseline of Originating Study in Joint Space Narrowing at Year 5
score on a scaleJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in Joint Space Narrowing at Year 50.59 (0.36 to 0.83)1.00 (0.84 to 1.17)0.68 (0.34 to 1.02)0.60 (0.37 to 0.83)————
SecondaryChange From Baseline of Originating Study in Duration of Morning Stiffness

Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

Time frame:
Baseline, Year 1
Reported as:
Mean · minutes
Change From Baseline of Originating Study in Duration of Morning Stiffness
minutesJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in Duration of Morning Stiffness-102.72 ± 155.27-73.53 ± 144.22——-75.07 ± 139.00-73.88 ± 149.55-68.74 ± 148.34-37.12 ± 61.34
SecondaryChange From Baseline of Originating Study in Duration of Morning Stiffness

Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

Time frame:
Baseline, Year 3
Reported as:
Mean · minutes
Change From Baseline of Originating Study in Duration of Morning Stiffness
minutesJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in Duration of Morning Stiffness-112.41 ± 159.78-77.78 ± 141.01——-84.60 ± 127.85-67.79 ± 154.05-90.61 ± 147.70-47.13 ± 52.97
SecondaryChange From Baseline of Originating Study in Duration of Morning Stiffness

Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

Time frame:
Baseline, Year 5
Reported as:
Mean · minutes
Change From Baseline of Originating Study in Duration of Morning Stiffness
minutesJADZ 4 Milligram (mg) BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in Duration of Morning Stiffness-111.45 ± 164.74-82.48 ± 137.23——-88.37 ± 146.73-91.57 ± 163.88-92.75 ± 125.39-45.89 ± 60.43
SecondaryChange From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores

The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.

Time frame:
Baseline, Year 1
Reported as:
Mean · score on a scale
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores
score on a scaleJADZ 4 Milligram (mg) BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
UK0.28 ± 0.260.23 ± 0.240.19 ± 0.260.20 ± 0.230.21 ± 0.220.19 ± 0.240.20 ± 0.26—
US0.19 ± 0.180.16 ± 0.170.13 ± 0.180.14 ± 0.160.14 ± 0.150.13 ± 0.160.14 ± 0.18—
SecondaryChange From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores

The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.

Time frame:
Baseline, Year 3
Reported as:
Mean · score on a scale
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores
score on a scaleJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
UK0.33 ± 0.240.24 ± 0.250.20 ± 0.260.21 ± 0.260.21 ± 0.220.22 ± 0.250.24 ± 0.24—
US0.23 ± 0.170.17 ± 0.170.15 ± 0.180.15 ± 0.180.14 ± 0.150.15 ± 0.170.17 ± 0.17—
SecondaryChange From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores

The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.

Time frame:
Baseline, Year 5
Reported as:
Mean · score on a scale
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores
score on a scaleJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
UK0.35 ± 0.240.26 ± 0.260.19 ± 0.250.20 ± 0.260.21 ± 0.220.22 ± 0.300.25 ± 0.26—
US0.24 ± 0.160.18 ± 0.180.13 ± 0.170.14 ± 0.180.15 ± 0.150.15 ± 0.200.18 ± 0.18—
SecondaryChange From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)

The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.

Time frame:
Baseline, Year 1
Reported as:
Mean · millimeter (mm)
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)
millimeter (mm)JADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)24.69 ± 28.5019.72 ± 28.1715.13 ± 26.7818.32 ± 26.3520.96 ± 24.5314.98 ± 30.2118.47 ± 27.31—
SecondaryChange From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)

The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.

Time frame:
Baseline, Year 3
Reported as:
Mean · mm
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)
mmJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)28.48 ± 29.8822.10 ± 28.0216.29 ± 25.3716.48 ± 30.2423.53 ± 24.7018.79 ± 30.0321.45 ± 29.64—
SecondaryChange From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)

The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.

Time frame:
Baseline, Year 5
Reported as:
Mean · mm
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)
mmJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)31.13 ± 28.1523.93 ± 28.4513.82 ± 29.5919.34 ± 27.4826.19 ± 27.0923.57 ± 31.6727.31 ± 27.19—
SecondaryPercentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10

The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤1081.6 (77.6 to 85.0)75.3 (72.6 to 77.9)68.6 (61.3 to 75.2)69.9 (65.1 to 74.4)52.5 (42.8 to 61.9)50.7 (44.8 to 56.6)73.3 (67.0 to 78.9)60.3 (49.2 to 70.4)
SecondaryPercentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10

The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤1073.3 (68.8 to 77.3)67.7 (64.8 to 70.5)60.4 (52.8 to 67.4)60.4 (55.3 to 65.3)49.5 (40.0 to 59.1)44.5 (38.8 to 50.4)61.4 (54.7 to 67.8)56.4 (45.4 to 66.9)
SecondaryPercentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10

The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

Time frame:
Years 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤1061.6 (56.8 to 66.1)61.1 (58.1 to 64.0)51.5 (44.0 to 58.9)54.6 (49.5 to 59.7)44.6 (35.2 to 54.3)35.4 (30.0 to 41.2)21.9 (16.8 to 28.0)56.4 (45.4 to 66.9)
SecondaryPercentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤ 2.8

The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤ 2.8
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤ 2.844.9 (40.2 to 49.7)28.3 (25.7 to 31.2)21.9 (16.3 to 28.7)25.1 (21.0 to 29.8)16.8 (10.8 to 25.3)13.5 (10.0 to 18.1)22.9 (17.7 to 29.0)14.1 (8.1 to 23.5)
SecondaryPercentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8

The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.840.1 (35.5 to 44.9)30.0 (27.3 to 32.8)21.9 (16.3 to 28.7)23.5 (19.4 to 28.1)22.8 (15.7 to 31.9)15.0 (11.2 to 19.7)18.6 (13.9 to 24.4)20.5 (13.0 to 30.8)
SecondaryPercentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8

The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.833.9 (29.5 to 38.6)25.0 (22.5 to 27.8)19.5 (14.3 to 26.2)22.4 (18.4 to 27.0)15.8 (10.0 to 24.2)12.8 (9.3 to 17.2)8.1 (5.1 to 12.6)19.2 (12.0 to 29.3)
SecondaryPercentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.2289.7 (86.5 to 92.3)81.4 (78.9 to 83.7)78.7 (71.9 to 84.2)75.4 (70.7 to 79.5)74.3 (65.0 to 81.8)69.3 (63.6 to 74.5)80.0 (74.1 to 84.8)48.7 (37.9 to 59.6)
SecondaryPercentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.2275.4 (71.1 to 79.3)70.4 (67.6 to 73.1)64.5 (57.0 to 71.3)63.4 (58.3 to 68.2)56.4 (46.7 to 65.7)54.4 (48.5 to 60.2)68.1 (61.5 to 74.0)47.4 (36.7 to 58.4)
SecondaryPercentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.2265.2 (60.5 to 69.6)58.5 (55.5 to 61.5)51.5 (44.0 to 58.9)51.4 (46.3 to 56.4)50.5 (40.9 to 60.0)39.4 (33.8 to 45.3)20.0 (15.2 to 25.9)39.7 (29.6 to 50.8)
SecondaryPercentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.385.4 (81.7 to 88.5)75.6 (72.9 to 78.1)72.8 (65.6 to 78.9)69.4 (64.5 to 73.9)65.3 (55.7 to 73.9)61.7 (55.8 to 67.2)75.2 (69.0 to 80.6)43.6 (33.1 to 54.6)
SecondaryPercentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.372.6 (68.1 to 76.6)64.8 (61.8 to 67.6)61.5 (54.0 to 68.5)58.5 (53.4 to 63.4)50.5 (40.9 to 60.0)47.8 (42.0 to 53.7)63.8 (57.1 to 70.0)38.5 (28.4 to 49.6)
SecondaryPercentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.362.8 (58.0 to 67.3)53.4 (50.3 to 56.4)46.7 (39.4 to 54.3)46.2 (41.1 to 51.3)46.5 (37.1 to 56.2)35.0 (29.6 to 40.9)19.5 (14.7 to 25.4)34.6 (25.0 to 45.7)
SecondaryChange From Baseline of Originating Study in Bone Erosion Score

The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.

Time frame:
Baseline, Year 1

No measurements were reported for this outcome.

SecondaryChange From Baseline of Originating Study in Bone Erosion Score

The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.

Time frame:
Baseline, Year 3
Reported as:
Least squares mean · score on a scale
Change From Baseline of Originating Study in Bone Erosion Score
score on a scaleJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in Bone Erosion Score0.85 (0.63 to 1.08)0.92 (0.76 to 1.07)0.59 (0.30 to 0.89)0.69 (0.49 to 0.89)——0.68 (0.32 to 1.03)—
SecondaryChange From Baseline of Originating Study in Bone Erosion Score

The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.

Time frame:
Baseline, Year 5
Reported as:
Least squares mean · score on a scale
Change From Baseline of Originating Study in Bone Erosion Score
score on a scaleJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Change From Baseline of Originating Study in Bone Erosion Score1.04 (0.77 to 1.32)1.18 (0.98 to 1.38)0.65 (0.28 to 1.01)0.98 (0.74 to 1.23)————
SecondaryHealthcare Resource Utilization

Number of visits to medical care providers related to treatment of Rheumatoid Arthritis (RA) outside of the clinical study. Reported here are healthcare consultations and emergency room consultations from end of originating study to end of participation in study JADY.

Time frame:
Baseline up to 84 Months
Reported as:
Number · consultations
Healthcare Resource Utilization
consultationsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Healthcare Consultations3134111082160457323805410717749
Emergency Room Consultations9524452131731544016
SecondaryPercentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11

SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤1181.6 (77.6 to 85.0)75.2 (72.5 to 77.8)70.4 (63.1 to 76.8)69.1 (64.2 to 73.6)53.5 (43.8 to 62.9)53.6 (47.7 to 59.5)72.4 (66.0 to 78.0)59.0 (47.9 to 69.2)
SecondaryPercentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11

SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤1173.3 (68.8 to 77.3)67.8 (64.9 to 70.6)60.9 (53.4 to 68.0)62.3 (57.2 to 67.1)48.5 (39.0 to 58.1)44.5 (38.8 to 50.4)60.0 (53.3 to 66.4)57.7 (46.6 to 68.0)
SecondaryPercentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11

SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤1161.3 (56.6 to 65.9)61.2 (58.2 to 64.1)51.5 (44.0 to 58.9)53.3 (48.2 to 58.3)46.5 (37.1 to 56.2)35.4 (30.0 to 41.2)23.3 (18.1 to 29.5)57.7 (46.6 to 68.0)
SecondaryPercentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3

SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.

Time frame:
Year 1 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.345.3 (40.6 to 50.1)28.9 (26.2 to 31.8)24.3 (18.4 to 31.2)23.5 (19.4 to 28.1)13.9 (8.4 to 21.9)13.1 (9.6 to 17.7)22.9 (17.7 to 29.0)14.1 (8.1 to 23.5)
SecondaryPercentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3

SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.

Time frame:
Year 3 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.339.9 (35.3 to 44.6)29.8 (27.1 to 32.6)22.5 (16.8 to 29.4)21.6 (17.7 to 26.1)19.8 (13.2 to 28.6)13.5 (10.0 to 18.1)15.7 (11.4 to 21.2)21.8 (14.1 to 32.2)
SecondaryPercentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3

SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.

Time frame:
Year 5 after entry into JADY
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3
percentage of participantsJADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg Baricitinib
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.334.8 (30.4 to 39.5)24.7 (22.1 to 27.4)20.7 (15.3 to 27.4)21.3 (17.4 to 25.8)13.9 (8.4 to 21.9)11.3 (8.1 to 15.6)8.1 (5.1 to 12.6)21.8 (14.1 to 32.2)
SecondaryPercentage of Participants With Relapse Event During the 96-Week Step-Down Period

Relapse is defined as a Clinical Disease Activity Index score \> 10. The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. Total number of participants at risk multiplied by estimate of cumulative event probability would need to be rounded up or down to get a whole number.

Time frame:
Week 0 through Week 96 of Step-down
Reported as:
Number · percentage of participants
Percentage of Participants With Relapse Event During the 96-Week Step-Down Period
percentage of participants2 mg Baricitinib Step-down4 mg Baricitinib Step-down
Week 1211.85.4
Week 2426.012.5
Week 3631.018.2
Week 4836.021.1
Week 6041.026.6
Week 7245.129.1
Week 8446.731.0
Week 9647.834.5

Adverse events

Collected over Baseline up to 84 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2 mg Baricitinib7/297 (2.4%)112/297 (37.7%)234/297 (78.8%)
4 mg Baricitinib70/2,579 (2.7%)517/2,579 (20%)1,532/2,579 (59.4%)
2 mg Baricitinib Step-Down4/592 (0.7%)164/592 (27.7%)270/592 (45.6%)
4 mg Baricitinib Step-Down4/594 (0.7%)178/594 (30%)315/594 (53%)
Most frequent serious events
Showing 10 of 652
Most frequent serious events
Event2 mg Baricitinib4 mg Baricitinib2 mg Baricitinib Step-Down4 mg Baricitinib Step-Down
PneumoniaInfections and infestations15/29734/257910/59212/594
OsteoarthritisMusculoskeletal and connective tissue disorders8/29742/25796/5925/594
CholelithiasisHepatobiliary disorders0/2978/25791/59210/594
Herpes zosterInfections and infestations5/29715/25792/5925/594
Ischaemic strokeNervous system disorders5/2971/25790/5920/594
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/29718/25795/5923/594
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/663/5482/1520/146
Acute myocardial infarctionCardiac disorders4/2977/25791/5921/594
Atrial fibrillationCardiac disorders4/29711/25791/5923/594
Urinary tract infectionInfections and infestations4/29712/25790/5923/594
Most frequent other events
Showing 10 of 24
Most frequent other events
Event2 mg Baricitinib4 mg Baricitinib2 mg Baricitinib Step-Down4 mg Baricitinib Step-Down
Upper respiratory tract infectionInfections and infestations58/297281/257946/59251/594
Urinary tract infectionInfections and infestations53/297241/257934/59252/594
BronchitisInfections and infestations48/297291/257944/59265/594
ArthralgiaMusculoskeletal and connective tissue disorders43/297155/25790/5920/594
NasopharyngitisInfections and infestations42/297291/257954/59258/594
Back painMusculoskeletal and connective tissue disorders42/297162/257935/59236/594
HypertensionVascular disorders33/297196/257938/59246/594
Herpes zosterInfections and infestations30/297160/257939/59253/594
InfluenzaInfections and infestations15/297147/257930/59256/594
CoughRespiratory, thoracic and mediastinal disorders28/297105/257935/59225/594

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)JADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg BaricitinibTotal
<=18 years000000000
Between 18 and 65 years38688115033586253199682358
>=65 years65209306831782215518
Sex: Female, Male
Sex: Female, Male(Participants)JADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg BaricitinibTotal
Female32684714433587275177712262
Male125243366830564412614
Race (NIH/OMB)
Race (NIH/OMB)(Participants)JADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg BaricitinibTotal
American Indian or Alaska Native355611262166143
Asian12232150946191672781
Native Hawaiian or Other Pacific Islander000100001
Black or African American1749107123264
White2756911192839827545731859
More than one race21712010023
Unknown or Not Reported010103005
Region of Enrollment
Region of Enrollment(Participants)JADZ 4 mg BaricitinibJADV 4 mg BaricitinibJADX 2 mg BaricitinibJADX 4 mg BaricitinibJADW 2 mg BaricitinibJADW 4 mg BaricitinibJAGS 4 mg BaricitinibJADA 4 mg BaricitinibTotal
United States68643910352136026488
Czechia0293100001456
Portugal3323000011
Russia35701070000122
Greece020024008
South Korea64368360072
Latvia080000008
Sweden300000003
Austria20003120017
Netherlands000010001
China04100001670208
Poland0661137922011156
Brazil160000014030
Slovenia050000005
Slovakia01737000027
France016006140036
Lithuania02100000021
Croatia002100069
Argentina872261544315400430
Romania01422000321
Hungary0308110001160
Japan8221541331100328
United Kingdom10831130026
Switzerland000007007
India2801627000071
Spain0289246190086
Canada138813320047
Turkey000012003
Belgium20738030041
Taiwan0122346000081
Denmark000023005
South Africa164000000056
Italy12036330027
Mexico39115814521012214
Israel00006210027
Australia001125140032
Germany112163130036
08

Study locations

409 sites
  • Arizona Arthritis & Rheumatology Research, PLLC
    Glendale, Arizona 85306, United States
  • Arizona Arthritis & Rheumatology Associates, P. C.
    Mesa, Arizona 85202, United States
  • Sun Valley Arthritis Center, LTD
    Peoria, Arizona 85381, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Valley Endocrine, Fresno
    Fresno, California 93720, United States
  • Allergy and Rheumatology Medical Clinic Inc
    La Jolla, California 92037, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Stanford University Hospital
    Palo Alto, California 94304, United States
  • Pacific Arthritis Center
    Santa Maria, California 93454, United States
  • Inland Rheumatology & Osteoporosis Medical Group
    Upland, California 91786, United States
  • Boulder Medical Center
    Boulder, Colorado 80304, United States
  • Denver Arthritis Clinic - Lowry
    Denver, Colorado 80230, United States
  • New England Research Associates
    Bridgeport, Connecticut 06606, United States
  • Clinical Research Center of CT/NY
    Danbury, Connecticut 06810, United States
  • Delaware Arthritis
    Lewes, Delaware 19958, United States
  • Orthopedic Research Institute
    Boynton Beach, Florida 33472, United States
  • Medallion Clinical Research Institute
    Naples, Florida 34102, United States
  • Sun Coast Clinical Research, Inc
    New Port Richey, Florida 34652, United States
  • Omega Research Consultants
    Orlando, Florida 32804, United States
  • Rheumatology Associates of Central Florida
    Orlando, Florida 32806, United States
  • Arthritis Research of Florida
    Palm Harbor, Florida 34684, United States
  • West Broward Rheumatology Associates, Inc
    Tamarac, Florida 33321, United States
  • AdventHealth Medical Group
    Tampa, Florida 33613, United States
  • Tampa Medical Group, P.A.
    Tampa, Florida 33614, United States
  • Intermountain Research Center
    Boise, Idaho 83702, United States
  • Deerbrook Medical Associates
    Vernon Hills, Illinois 60061, United States
  • Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Diagnostic Rheumatology and Research
    Indianapolis, Indiana 46227, United States
  • Goldpoint Clinical Research LLC
    Indianapolis, Indiana 46260, United States
  • Klein and Associates MD, PA
    Cumberland, Maryland 21502, United States
  • West Michigan Rheumatology
    Grand Rapids, Michigan 49546, United States
  • Borgess Rheumatology
    Kalamazoo, Michigan 49009, United States
  • Advanced Rheumatology, PC
    Lansing, Michigan 48910, United States
  • Office: Dr. Fiechtner, Justus
    Lansing, Michigan 48910, United States
  • Arthritis and Osteporosis Treatment and Research Center
    Flowood, Mississippi 39232, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • Clayton Medical Research
    Saint Louis, Missouri 63117, United States
  • Arthritis Consultants, Inc.
    Saint Louis, Missouri 63141, United States
  • Dr. George Timothy Kelly
    Las Vegas, Nevada 89128, United States
  • (AOA) Arthritis & Osteoporosis Associates
    Freehold, New Jersey 07728, United States
  • Ocean Rheumatology, PA
    Toms River, New Jersey 08755, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • The Center for Rheumatology
    Albany, New York 12203, United States
  • Drug Trials of America
    Hartsdale, New York 10530, United States
  • Allergy Asthma Immunology of Rochester, AAIR Research Ctr
    Rochester, New York 14618, United States
  • Asheville Rheumatology & Osteoporosis Research Assoc, PA
    Asheville, North Carolina 28803, United States
  • Arthritis and Osteoporosis Consultants of the Carolinas
    Charlotte, North Carolina 28207, United States
  • Paramount Medical Research
    Middleburg Heights, Ohio 44130, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Healthcare Research Consultant
    Tulsa, Oklahoma 74135, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • East Penn Rheumatology Associates
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Arthritis Group
    Philadelphia, Pennsylvania 19152, United States
  • Clinical Research Center of Reading,LLC
    Wyomissing, Pennsylvania 19610, United States
  • Carolina Rheumatology and Neurology Associates
    Myrtle Beach, South Carolina 29572, United States
  • Pioneer Research Solutions
    Cypress, Texas 77429, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Accurate Clinical Research
    League City, Texas 77573, United States
  • Arthritis & Osteoporosis Associates LLP
    Lubbock, Texas 79424, United States
  • Accurate Clinical Research
    Webster, Texas 77598, United States
  • Center for Arthritis and Rheumatic Diseases, PC
    Chesapeake, Virginia 23320, United States
  • Western Washington Arthritis Clinic
    Bothell, Washington 98021, United States
  • Kadlec Clinic Rheumatology
    Kennewick, Washington 99336, United States
  • The Vancouver Clinic
    Vancouver, Washington 98664, United States
  • Rheumatology and Immunotherapy Center
    Franklin, Wisconsin 53132, United States
  • Hospital Italiano Regional del Sur
    Bahia Blanca, Buenos Aires B8000HXM, Argentina
  • Atencion Integral en Reumatología
    Ciudad Autonoma de Buenos Aire, Buenos Aires C1426AAL, Argentina
  • Instituto de Investigaciones Clínicas Mar del Plata
    Mar del Plata, Buenos Aires 7600, Argentina
  • Centro de Investigaciones Medicas Mar del Plata
    Mar del Plata, Buenos Aires B7600FYK, Argentina
  • CER Instituto Medico
    Quilmes, Buenos Aires B1878DVC, Argentina
  • Instituto de Investigaciones Clinicas Quilmes
    Quilmes, Buenos Aires B1878GEG, Argentina
  • Instituto Medico de Alta Complejidad San Isidro
    San Isidro, Buenos Aires B1642, Argentina
  • CENIT Centro de Neurociencias, Investigación y Tratamiento
    Caba, Ciudad Autonoma Buenos Aires C1125ABD, Argentina
  • Instituto Centenario
    Caba, Ciudad Autonoma De Buenos Aire 1204, Argentina
  • Centro de Enfermedades del Higado y Aparato Digestivo
    Rosario, Santa Fe S2000CFJ, Argentina
  • Instituto CAICI SRL
    Rosario, Santa Fe S2000, Argentina
  • CIR Centro de Investigacions Reumatologicas
    San Miguel de Tucuman, Tucuman T4000BRD, Argentina
  • Centro Medico Privado de Reumatologia
    SAN M. DE Tucuman, Tucumán T4000AXL, Argentina
  • Consultorios Asociados de Endocrinologia
    Ciudad Autonoma Buenos Aires, C1425AGC, Argentina
  • Organizacion Medica de Investigacion - OMI
    Ciudad Autonoma de Buenos Aire, C1015ABO, Argentina
  • Centro De Osteopatias - Comlit
    Ciudad Autonoma de Buenos Aire, C1128AAF, Argentina
  • Hospital Ramos Mejia
    Ciudad Autonoma de Buenos Aire, C1221ADC, Argentina
  • Centro de Medicina Familiar Mindout Research
    Ciudad Autonoma de Buenos Aire, C1417EYG, Argentina
  • Consultorios Reumatologicos Pampa
    Ciudad Autonoma de Buenos Aire, C1428DZF, Argentina
  • CCBR Buenos Aires
    Ciudad Autonoma de Buenos Aire, C1430CKE, Argentina
  • CEMIC Saavedra
    Ciudad Autonoma de Buenos Aire, C1431FWO, Argentina
  • CENUDIAB
    Ciudad Autonoma de Buenos Aire, C1440AAD, Argentina
  • Instituto Medico Strusberg
    Cordoba, X5000EDC, Argentina
  • Hospital Italiano de Cordoba
    Cordoba, X5004BAK, Argentina
  • Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC
    Cordoba, X5008HHW, Argentina
  • Hospital Privado Centro Medico de Cordoba SA
    Cordoba, X5016KEH, Argentina
  • Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan
    San Juan, J5402DIL, Argentina
  • Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Combined Rheumatology Practice (CRP)
    Kogarah, New South Wales 2217, Australia
  • Coast Joint Care
    Maroochydore, Queensland 4558, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, Victoria 3065, Australia

Showing the first 100 of 409 sites across 38 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, Winthrop KL. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022 Mar;81(3):335-343. doi: 10.1136/annrheumdis-2021-221276. Epub 2021 Oct 27. PubMed 34706874 ↗
  • Wells AF, Jia B, Xie L, Valenzuela GJ, Keystone EC, Li Z, Quebe AK, Griffing K, Otawa S, Haraoui B. Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study. Rheumatol Ther. 2021 Jun;8(2):987-1001. doi: 10.1007/s40744-021-00317-9. Epub 2021 May 24. PubMed 34028703 ↗
  • Fleischmann R, Takeuchi T, Schiff M, Schlichting D, Xie L, Issa M, Stoykov I, Lisse J, Martinez-Osuna P, Rooney T, Zerbini CAF. Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. Arthritis Care Res (Hoboken). 2020 Aug;72(8):1112-1121. doi: 10.1002/acr.24007. PubMed 31233281 ↗
  • Tanaka Y, Fautrel B, Keystone EC, Ortmann RA, Xie L, Zhu B, Issa M, Patel H, Gaich CL, de Bono S, Rooney TP, Taylor PC. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Ann Rheum Dis. 2019 Jul;78(7):890-898. doi: 10.1136/annrheumdis-2018-214529. Epub 2019 Apr 30. PubMed 31040122 ↗
  • Winthrop KL, Bingham CO 3rd, Komocsar WJ, Bradley J, Issa M, Klar R, Kartman CE. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Res Ther. 2019 Apr 18;21(1):102. doi: 10.1186/s13075-019-1883-1. PubMed 30999933 ↗
  • Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15. Erratum In: J Rheumatol. 2019 Dec;46(12):1648-1649. doi: 10.3899/jrheum.171361.C1. PubMed 30219772 ↗
  • Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP, Schlichting DE, Zuckerman SH, Emery P. Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis. Arthritis Rheumatol. 2018 Dec;70(12):1923-1932. doi: 10.1002/art.40680. Epub 2018 Oct 22. PubMed 30058112 ↗
  • Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20. PubMed 29463520 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Nov 2020, 88 months.

Results were first posted in Feb 2022, 1 year 2 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 88 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2013
First posted
Jun 24, 2013
StartActual
Jun 27, 2013
Primary completionActual
Nov 12, 2020
CompletionActual
Nov 12, 2020
Results first posted
Feb 1, 2022
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01885078
Responsible party
Sponsor
First posted
Jun 24, 2013
Start date
Jun 27, 2013
Primary completion
Nov 12, 2020
Completion
Nov 12, 2020
Results posted
Feb 1, 2022
Last update
Apr 25, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion